Brief: Gadopiclenol Marketing Authorization Dossier Submissions Accepted For Review By EMA And FDA
Guerbet SA GRBT.PA :
* GADOPICLENOL MARKETING AUTHORIZATION DOSSIER SUBMISSIONS
ACCEPTED FOR REVIEW BY EMA AND FDA
* GUERBET SA - US-FDA HAS ACCEPTED REQUEST FOR PRIORITY
REVIEW
WITH A GOAL DATE FOR TAKING ACTION ON AN APPLICATION BY
SEPTEMBER 21 FOR GADOPICLENOL
Source text for Eikon: ID:nPn1nvYd5a
Further company coverage: GRBT.PA
Recent news on Guerbet SA
See all newsBrief: Guerbet Q1 Revenue At EUR 177.4 Mln
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates